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ABSTRACT: 
BACKGROUND: Cancer related fatigue (CRF) is one of the most common side effects of 
cancer and cancer treatment.  Being able to accurately screen for and assess CRF will improve 
access to and prescriptions for interventions.  Valid and reliable measures to screen for and 
assess CRF need to be identified. PURPOSE: To identify and recommend reliable, valid and 
clinically useful tools to screen for and assess CRF among those treated for cancer. METHODS: 
A systematic review of the literature was conducted to assess the published psychometric 
properties and clinical feasibility of each method identified. Task Force members independently 
reviewed each measure using the Cancer EDGE Rating Form. RESULTS:  Review of 136 
studies resulted in recommendations for 14 questionnaires.  Five unidimensional and nine 
multidimensional questionnaires are recommended by the Oncology EDGE Task Force.    
CONCLUSION:  The 10-point Numeric Rating Scale for Fatigue is best as a screening tool, 
while the Multi-dimensional Fatigue Symptom Inventory is a highly recommended 
multidimensional tool. Ease of screening can promote referral for interventions, while thorough 
assessment drives appropriate interventions. 
KEYWORDS:  Psychometrics, measurement, surveys or questionnaires 
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INTRODUCTION AND BACKGROUND 
Cancer-Related Fatigue (CRF) is one of the most common side effects of cancer 
treatment and is not specific to any cancer diagnosis, but rather impacts up to 96% of survivors at 
any point along the survivorship continuum.1  Cancer-related fatigue is defined as a distressing, 
persistent, subjective sense of physical, emotional and /or cognitive tiredness or exhaustion 
related to cancer or its treatment that is not proportional to recent activity and interferes with 
usual functioning. 2 One of the most important considerations, and one often used to assist in 
diagnosis, is the criterion that CRF is not relieved by rest.2 This sense of fatigue is perceived not 
only physically, but also cognitively and emotionally.3  Fatigue is reported most consistently in 
those undergoing chemotherapy, whether in isolation or in conjunction with radiation, but may 
persist after treatment.4,5 Research indicates that for at least a subset of patients, CRF may be a 
significant issue long into survivorship, with a negative impact on quality of life (QOL).6,7    
 Diagnosing CRF is complicated by the multidimensional nature of the fatigue, such as 
whether it is centrally or peripherally mediated,8 and that this fatigue may be secondary to other 
side effects of treatment, such as anemia. Along with anemia, cancer treatments themselves, 
cancer recurrence, pain, medications, sleep disturbances, psychosocial issues including 
depression and anxiety, malnutrition, decreased functioning, increased proinflammatory 
cytokines, and immobility are all contributing factors.9,10  Other pathophysiological 
considerations for fatigue include: abnormality in growth factors, circadian rhythm modulation, 
hypothalamic–pituitary–adrenal axis disruption, serotonin dysregulation, vagal afferent 
activation, abnormalities of the generation of and/or use of adenosine triphosphate, and 
mitochondrial biogenesis9,11,12  Despite this multifactorial causality for CRF, health care 
providers must be able to screen for CRF and make appropriate referrals, including to physical 
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therapist (PT)s. PTs in turn, must be able to accurately and comprehensively assess CRF to 
appropriately treat this debilitating condition. 
 Accurate screening and assessment are dependent upon tools that demonstrate strong 
psychometric properties. Ideal screening tools are simple and efficient to administer, while 
assessment tools should provide a deeper understanding of the problem. The tools must be valid, 
reliable, and if used as an outcome measure, sensitive to change. Following the ongoing work of 
the Evidence Database to Guide Effectiveness (EDGE) task force of the Oncology Section of the 
American Physical Therapy Association, a review of tools purported to screen for and assess 
CRF were analyzed for the strength of their psychometric properties. The purpose of this 
systematic review is to identify a core set of both screening and assessment measures that are 
reliable, valid, responsive, and clinically feasible to assess CRF. 
  
METHODS 
Search Strategy 
The task force conducted a systematic review of methods and tools used to screen for and assess 
CRF in order to identify reliable, valid, and clinically feasible methods that are responsive to 
change which measure CRF in persons diagnosed with cancer. The primary literature search took 
place May, 2016 through September, 2016 using five electronic databases: Google Scholar, 
PubMed/Medline, CINAHL, Embase, and PEDro. Primary search terms used included: cancer, 
CRF, reliability, and validity. Search terms included:  “cancer related fatigue,” “cancer-related 
fatigue,” “fatigue AND cancer,” AND measures, measurements, questionnaires, AND 
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psychometrics. Additional search terms for the specific clinical measuring tools are in the 
Appendix. A secondary search was completed in August, 2017 to update any new evidence. 
Article Selection 
To be included in this review, studies (1) had to have been published in English; (2) described 
tools used to screen for or assess CRF; (3) reported psychometric properties of the tools used to 
screen or assess CRF; (4) presented clinically feasible methods for the screening and assessment 
of CRF; (5) included the adult population (≥18); and (6) were published between January 1, 1997 
– August, 2017. Excluded articles demonstrated a lack of evidence, included the pediatric 
population, or were not considered to be a fatigue screening or assessment tool. This final 
exclusion criterion included any scale that evaluated the impact of fatigue or CRF on health-
related QOL.  If a study published prior to 1997 was deemed a key article to either explain the 
measure or was foundational in establishing the psychometrics of a test, it was then included. 
After retrieving all articles, the duplicates were removed. All studies were initially screened 
based on title and abstract, and then on the basis of full-text. 
Data Extraction and Analysis  
Each article classified as either unidimensional or multidimensional according to the Breast 
Cancer EDGE Task Force Outcomes: Evidence-based Cancer-related Fatigue Measurement 
Tools.13 Unidimensional tools are commonly considered a fatigue-specific tool with one or a few 
questions to identify the prevalence and severity of CRF while multidimensional measures often 
examine the effect of CRF across several domains of patient function that may include 
behavioral, cognitive, somatic, and affective. For the purposes of this review, the authors 
consider unidimensional tools to be those that often serve to screen for the presence of the 
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condition or assess only a single factor of fatigue, while the multidimensional tool provides a 
more thorough assessment of the fatigue.  
Each article was reviewed by two teams of two reviewers who independently performed 
data extraction using the Cancer EDGE Task Force Rating Form (Figure 1 available online). 
Psychometric properties included in the Cancer EDGE Task Force Rating Form consist of 
reliability, validity, ceiling/floor effects, sensitivity to change, and clinical utility. Because CRF 
tools are self-report questionnaires, the types of reliability evaluated included test-retest 
reliability and internal consistency. Internal consistency examines whether the items on different 
questionnaires reliably measure the same thing. The following criteria were applied to describe 
the strength of the psychometric properties: excellent reliability = >0.90; good reliability = 0.76-
0.89; moderate reliability = 0.50-0.75; and poor reliability <0.50.14  Criterion and construct 
validity including concurrent, divergent, discriminative, and predictive validity values are 
reported when available, as well as measures assessing responsiveness to change such as 
minimal detectable change (MDC) and minimal clinically important difference (MCID). Each 
reviewer then rated the measure using the updated Cancer EDGE Rating Scale.15 Any 
discrepancies in ratings were discussed with all four reviewers until consensus was obtained.  
 
RESULTS 
The literature search initially found 626 articles that included CRF measures. After duplicate 
studies were removed and the inclusion criteria were applied, 136 articles were reviewed. See 
Figure 2 for flow chart. 
Five unidimensional measures and nine multi-dimensional tools are recommended for 
use. Among the unidimensional CRF questionnaires, three are highly recommended (4 rating): 
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Modified Brief Fatigue Inventory (mBFI); Cancer-Related Fatigue Distress Scale; and a 10-point 
Rating Scale for Fatigue. Two unidimensional tools are recommended (3 rating): the MD 
Anderson Symptom Inventory and Wu Cancer Fatigue Scale. Tables 1 and 2 summarize the 
features and ratings for the recommended measures. Seven scales received ratings of 1 (not 
recommended) or 2 (reasonable to use), and are not reviewed in detail. Table 3 lists measures 
that are reasonable to use or not recommended, with summary rationale. Table 4 provides a 
summary of the clinical usefulness of the recommended measures. 
Only one multi-dimensional tool is highly recommended by the Cancer EDGE Task 
Force and that is the Multi-dimensional Fatigue Symptom Inventory. Eight CRF measurement 
tools received a recommended rating of 3: Bi-dimensional Fatigue Scale, Cancer Fatigue Scale, 
Fatigue Symptoms Inventory, Multidimensional Fatigue Inventory, Piper/ Quick Piper, Profiles 
of Mood States, PROMIS Cancer Fatigue Short Form, and Schwartz Cancer Fatigue Scale. See 
Tables 5 (reliability and sensitivity to change) and Table 6 (validity) for details on the 
psychometric properties of all recommended (rated 3 and 4) tools.  
 
DISCUSSION 
Accurate diagnosis of CRF is important to guide treatment. Researchers propose that four 
criteria be considered to establish the diagnosis of CRF, including: 1) a period of two weeks or 
longer within the preceding month during which significant CRF or diminished energy was 
experienced each day or almost every day along with additional CRF-related symptoms; 2) the 
experience of CRF resulting in significant distress or impairment of function; 3) the presence of 
clinical evidence suggesting that CRF is a consequence of cancer or cancer therapy; and 4) 
fatigue is not primarily a consequence of a concurrent psychiatric condition, such as major 
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depression.12 Before the diagnosis of CRF is made, it is important that the results of a full 
medical workup rule out other causes of fatigue such as anemia, endocrine dysfunction, or 
fatigue directly related to prescription medication.  The standardization and comprehensive 
fatigue assessment guidelines and criteria for clinical practice developed by National 
Comprehensive Cancer Network (NCCN) were developed to improve assessment and 
management of CRF. This review provides evidence to consider when determining the most 
valid and reliable tools to screen for and assess CRF. 
This systematic review resulted in three highly recommended unidimensional tools and a 
single multidimensional tool to screen for or measure CRF. These tools have strong 
psychometric properties in the population of interest and can be easily used by clinicians. Several 
other tools are recommended; these have good psychometric properties in the population of 
interest and are clinically feasible. 
Among the unidimensional tools that are either rated 3 or 4 by this task force, the use of a 
10-point Rating Scale of Fatigue stands out as the most efficient method to screen for the 
presence of CRF. An understanding of numeric rating scales (NRS) and visual analog scales 
(VAS) is warranted when considering this tool.  Numeric rating scales, where 0 = absence of a 
construct and 10 = worst imaginable experience of a construct, are commonly used clinically to 
assess the severity of symptoms, and most commonly used for pain assessment.  The VAS, too, 
is a frequently employed tool to measure severity of symptoms, and consists of a 100 mm with 
markings from 0 to 10 every 10 mm along the line.  In evaluating the literature, the authors found 
a total of 11 studies which utilized either the NRS or the VAS in examining psychometric 
qualities of instruments evaluating fatigue.  Further analysis of these research studies reveals that 
the term NRS is often used to mean VAS (a written expression of severity); in one case the VAS 
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was converted to a NRS for telephone interviewing, yet was not identified as a NRS in study 
methodology.  While this overlap of terms and rating techniques results in inconsistencies in 
administration, the overall intent of both methods is based on the premise of rating severity as 
low to high on a 10-point scale.  In the literature search completed by this task force, these 10-
point scales had multiple names:  the Numeric Rating Scale for Fatigue, the Visual Analog Scale 
for Fatigue, the One-Item Fatigue Scale, the Single-Item Screening Tool, and the Fatigue 
Numerical Scale. 
The simplicity of a 10-point Numeric Rating Scale for Fatigue make it an ideal screening 
tool. The question “How would you rate your fatigue on a scale of 0 to 10 with 0 being no 
fatigue and 10 being the worst possible fatigue?”, whether verbally or along a 100 mm line, is 
quick and focused.  This simple question captures the presence and intensity of fatigue, and 
easily can be used to drive a referral for greater assessment. 2 The simplistic nature of the 
question belies the strength of the psychometric properties, which demonstrate good test-retest 
reliability (r=0.88) and convergent validity with the Fatigue Symptom Index, the Functional 
Assessment of Chronic Illness Therapy – Fatigue (FACIT-F), and the Multidimensional Fatigue 
Inventory (general fatigue).16-18  This tool also demonstrates moderate to good sensitivity (0.70 - 
0.85) and specificity (0.61 – 0.71).16,19 The NCCN Guidelines for CRF recommend a referral 
with a score of four or greater.2 While the NCCN Guidelines are most frequently followed, an 
empirical cut score of 5 was derived by taking into consideration an analysis of specificity and 
sensitivity and based on the area under the curve (0.71).19 Given that the ease and level of 
efficiency in administration is high, the a 10-point Rating Scale for Fatigue receives a highly 
recommended score by the task force and is an ideal screening tool.  
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Both the modified Brief Fatigue Inventory (mBFI) and the Cancer Related Fatigue 
Distress Scale, while unidimensional, are more time intensive which may discourage their use  to 
screen for fatigue. The mBFI examines the severity and impact of fatigue on daily functioning in 
the previous 24 hours through a nine-item questionnaire that can be administered via self-report, 
interview, or via interactive voice recording. Each item is rated 0-10, and a global score of 
fatigue is the average of all items. The mBFI has good-excellent test-retest reliability (0.89-
0.95),20 and demonstrates both construct validity with the Multidimensional Fatigue Symptom 
Inventory (short form) (r=0.814)20 and concurrent validity with the FACIT-Fatigue scale (r=-
0.838-0.903).21  The Cancer Related Fatigue Distress Scale assesses the dimension of distress 
related to fatigue and examines this in terms of physical, social, psychological, cognitive, and 
spiritual areas. This 20-item self-report scale evaluates statements on a 0-10 scale; higher 
numbers indicate greater distress.22  The Cancer Related Fatigue Distress Scale demonstrates 
excellent item consistency (α=0.98), and good convergent validity with the Wu Cancer Fatigue 
Scale (r=0.84), as well as good predictive validity (r=0.83).23  Understanding the impact of 
fatigue and the distress experienced, can guide clinicians in treatment decisions. 
The MD Anderson Symptom Inventory and the Wu Cancer Fatigue Scale, while 
recommended by the task force, do not possess the strengths of psychometric properties or ease 
of use that the highly recommended measures possess. The MD Anderson Symptom Inventory is 
a 19-item self-report scale which examines severity and interference of CRF; higher scores 
indicate greater levels of fatigue.24  This scale demonstrates acceptable levels of convergent 
validity with the Brief Fatigue Inventory (r=0.84), but lower levels with the European 
Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC 
QLQ-30) (r=-0.60), and lacks sensitivity to change.25  The Wu Cancer Fatigue Scale scores nine 
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items on a 1-5 Likert scale with higher values indicating greater fatigue.26  The internal 
consistency of items is high (α=0.95),27 but the convergent, concurrent, and predictive validity 
levels are lower (see Tables 5 and 6). Both are acceptable for use as they take less than 10 
minutes to complete, however, the a 10-point Rating Scale for Fatigue remains a better screening 
tool, and the mBFI a stronger unidimensional tool for assessing CRF. 
The only highly recommended multi-dimensional fatigue tool recommended by the 
Cancer EDGE task force, the Multidimensional Fatigue Symptom Inventory (Short Form), 
examines fatigue in the context of global, somatic, cognitive, and behavioral manifestations 
across general, physical, emotional, and mental domains.28,29  This scale, with 30 self-reported 
items, takes less than 10 minutes to complete, with each item scored on a five-point Likert scale; 
higher numbers indicate greater fatigue. The Multidimensional Fatigue Symptom Inventory 
provides a comprehensive examination of fatigue across multiple domains with a high sensitivity 
to change, an ability to discriminate not only between those with and without fatigue but among 
those with differing levels of function due to fatigue,28 and demonstrates moderate to high 
correlations with other established scales (Fatigue Symptom Inventory, r=0.82 and SF-36, r=-
0.82).29   
The recommended multidimensional tools outlined in Table 2 are adequate alternatives 
for the clinicians to comprehensively assess CRF. Each takes less than 10 minutes to complete, 
and demonstrates adequate psychometric properties. The 11-item self-report Bidimensional 
(Chalder) Fatigue Scale measures the extent and severity of fatigue on a four- point Likert scale 
with a higher global score indicating greater fatigue, or two subscale scores (physical and 
psychological).30  Specifically designed to assess CRF, the Cancer Fatigue Scale is a 15-item 
self-report scale that takes approximately two minutes to complete. It examines fatigue across the 
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physical, affective, and cognitive domains using a five-point Likert scale with higher scores 
indicating greater fatigue.31  The Fatigue Symptom Inventory uses 14 items scored 0-10 to assess 
the severity, frequency, and daily pattern of fatigue as well as how it interferes with QOL, scored 
low to high either globally or by subscale.32  The Multidimensional Fatigue Inventory, a 20 item, 
five-point Likert questionnaire scored inversely (higher values mean lower fatigue), measures 
fatigue across general, mental, and physical domains with consideration for reduced activity and 
reduced motivation.33  As one of the more well known fatigue measures, the Piper (22 
items)/Quick Piper (15 items) Fatigue Scale assess fatigue across the temporal, sensory, 
affective, and intensity/severity domains using a 0-10 visual analog scale with higher scores 
indicating greater fatigue.34  The Profile of Mood States-2 assesses fatigue-inertia as one of the 
seven mood states, using 35 items scored on a five-point Likert scale with higher values 
indicating greater levels within each mood state.35  The Patient Reported Outcome Measure 
Information System (PROMIS) assesses fatigue in the past week using a seven item self-report 
scale, scored with a one-five Likert where higher scores indicate greater fatigue.36  And lastly, 
the Schwartz Cancer Fatigue Scales, developed specifically for CRF, assesses fatigue across four 
scales – physical, emotional, cognitive, temporal – through a 28 item five-point Likert self-
report, with higher scores indicating greater fatigue.37 
Limitations to this review need to be noted as the clinician uses this information to 
inform practice.  As with all reviews, new data may become available after completion of the 
literature search and are not included here.  This review does not assess study quality, and it is 
possible that psychometric evaluation is based on small sample sizes or studies with 
methodological flaws.  Lastly, while this review is intended to evaluate measures to assess CRF, 
some fatigue instruments lack validation in the cancer population. 
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Cancer-related fatigue remains one of the most prevalent comorbidities of a cancer 
diagnosis along the survivorship continuum. As such, knowing the fatigue status of survivors is 
essential in order to design appropriate and comprehensive treatment plans and to monitor 
patient status and the effectiveness of those treatment programs. While this review defines 
reliable, valid and clinically useful tools for use in screening for and assessing CRF, clinicians 
need to consider whether the tool will be used for screening or for assessment.  By combining the 
findings from this investigation with patient needs, appropriate referral and intervention can 
occur.  
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Legends: 
Table 1:  Summary of Recommended Outcome Measures - Unidimensional 
Table 2: Summary of Recommended Outcome Measures – Multi-dimensional 
Table 3:  Summary of Outcome Measures with Cancer EDGE Ratings of 1 or 2 
Table 4:  Clinical Usefulness of Recommended Measures 
Table 5:  Psychometric properties of Recommended Measures Related to Reliability and 
Responsiveness 
Table 6:  Psychometric properties of Recommended Measures Related to Validity 
 
Figure 1:  Cancer EDGE Task Force Rating Scale (online only) 
Figure 2:  PRISMA Flow of literature search 
 
Appendix:  Search Terms 
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Appendix: Search Terms 
 
Bidimensional Fatigue Scale 
Brief Fatigue Inventory 
Cancer Fatigue Scale 
Cancer Related Fatigue Distress Scale 
Diagnostic Interview Guide for Cancer Related Fatigue 
European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire  (EORTC) 
Fatigue and Functional Impact Scale 
Fatigue Barriers Scale 
Fatigue Management Barriers Questionnaire (FMBQ) 
Fatigue Pictogram  
Fatigue Scale- Children  
Fatigue Symptom Checklist 
Fatigue Symptom Inventory 
Four-Item Fatigue Scale 
Functional Assessment of Cancer Therapy 
General Fatigue Scale 
Illness Perception Questionnaire 
Karnofsky Performance Scale 
Lee Fatigue Scale 
MD Anderson Symptom Inventory 
Measuring Fatigue in Childhood Cancer 
Medical Outcome Study QOL Short Form 36 
Memorial Symptom Assessment Scale- Short Form (MASAS-SF) 
Modified Brief Fatigue Inventory 
Multidimensional Assessment of Fatigue 
Multidimensional Fatigue Inventory (MFI) 
Multidimensional Fatigue Symptom Inventory (MFSI) 
One-Item Fatigue Scale 
PEDS QL Multidimensional Fatigue Scale 
Piper Fatigue Scale 
Play Performance Scale for Children 
Profile of Mood States (POMS) 
PROMIS Cancer Fatigue Short Form 
QOL for Children with Cancer 
Quick Piper Scale 
Rotterdam Symptom Checklist 
Schwartz Cancer Fatigue Scale 
Spielberger State Trait Anxiety 
Visual Analog Scale 
Wu Cancer Fatigue Scale 
Zung Self Rating Depression Scale 
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Figure 2.  Cancer EDGE Rating Scale 
 
4 Highly Recommended 
The outcome measure has excellent psychometric properties 
(reliability and validity AND have available data to guide 
interpretation) in condition of interest and excellent clinical 
utility (≤20 min, equip in clinic, no copyright payments, easy to 
score); the measure is free or reasonably accessible 
to a broad range of providers. 
3 Recommended 
The outcome measure has good psychometric properties (may 
lack some info about reliability, validity, responsiveness) in the 
population of interest and good clinical utility (>20 min, some 
equip, training, copyright fee); OR has excellent psychometric 
properties but is not free and may require access to 
specialized testing equipment that is beyond the means of 
many clinicians or clinics. 
 
2 Reasonable to Use 
Limited study in target group; the outcome measure has good 
or excellent psychometric properties and clinical utility in a 
related population, but insufficient study in target population to 
support higher recommendation. 
1 Not Recommended The outcome measure has poor psychometric properties and/or poor clinical utility 
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Table 1 
Summary of Recommended Outcome Measures - Unidimensional 
Measure EDGE Rating Features 
Brief Fatigue Inventory/ Modified-
Brief Fatigue Inventory9,38-49 4 
• Severity of fatigue in the last 
24 hours 
• Less than 5 minutes to 
complete 
• Used in a cancer population 
Cancer Related Fatigue Distress 
Scale22,26,27 4 
• Assesses cancer related 
fatigue distress  
• 10 minutes to complete 
• Used in a cancer population 
10-point Rating Scale for 
Fatigue16-19 4 
• Assesses the presence and 
intensity of fatigue 
• Easy to use  
• Takes less than one minute to 
administer 
• Ideal as a screening tool 
• Used on those with thoracic 
malignancy 
MD Anderson Symptom 
Inventory24,25,50 3 
• Assesses fatigue severity over 
24 hours 
• Takes 2 -5 minutes to 
complete       
• Used in cancer populations                                                               
Wu Cancer Fatigue Scale26,27 3 
• 9 Item self-report 
• Less than 5 minutes to 
complete  
• Used with a breast cancer 
population 
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Table 2 
Summary of Recommended Outcome Measures – Multi-dimensional    
Measure EDGE Rating Features 
Multidimensional Fatigue 
Symptom Inventory28,29,51,52 4 
• Multiple areas assessed  
• Takes over 10 minutes to 
administer 
• Used with multiple different types 
of cancer 
Bi-dimensional (Chalder) 
Fatigue Scale30,53,54 3 
• Extent and severity of fatigue 
• Takes about 5 minutes to 
complete 
• Used in populations of multiple 
cancers 
Cancer Fatigue 
Scale31,46,48,55,56 3 
• Physical, affective, and cognitive 
fatigue related to cancer 
• 2-3 minutes to complete 
• Used in a population with various 
stages of cancer 
Fatigue Symptom 
Inventory16,29,32,38,48,57-62 3 
• Assesses the frequency, severity, 
and disruptiveness of fatigue  
• Five minutes to complete 
(although 27% individuals 
reported difficulty with 
questionnaire)  
Multidimensional Fatigue 
Inventory33,48,63-65 3 
• Assesses fatigue in the past 24 
hours 
• Less than 10 minutes to complete 
• Used with a cancer population 
Piper/Quick Piper34,48,66-75 3 
• Assesses fatigue at current time 
• Five minutes to complete 
• Used in populations with breast 
and lung cancer.  
Profile of Mood 
States42,44,46,48,66,67,73,76 3 
• Assesses mood over the past 
week 
• Has a fatigue subscale 
• Takes 5-7 minutes to complete 
• Used in a population with breast 
cancer 
Patient Reported Outcome 
Measure Information System 
(PROMIS) Cancer Fatigue 
Short Form36 
3 
• Assess fatigue over the past 
seven days 
• Unknown time to complete 
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• Used in a population with prostate 
and hematologic cancer 
Schwartz Cancer Fatigue 
Scale37,48,77 3 
• Assess fatigue in the past 2-3 
days 
• Takes about 4 minutes to 
complete 
• Used in a population with multiple 
cancers 
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Table 3 
Summary of Outcome Measures with Cancer EDGE Ratings of 1 or 2    
Measure EDGE Rating Strengths/Weaknesses 
Four Item Fatigue Scale36,37 2 • Four questions  
• Lower psychometric strength 
Lee Fatigue Scale60,74 2 
• Not tested in cancer 
population 
• Minimal psychometric testing 
Visual Analog Scale - Fatigue52,75 2 
• 18 questions on a 10 cm line 
• High internal reliability and 
concurrent validity established 
• May not discriminate between 
fatigue and sleepiness 
Zung One Item Self-Rating 
Depression Scale55 2 
• A depression scale validated 
for fatigue 
• Includes a question “I get tired 
for no reason”.  
• Possible use as a screen 
Multidimensional Assessment of 
Fatigue60 1 
• Multiple questions that take a 
long time to complete 
• Lacks sensitivity to change 
Fatigue Pictogram76,77 1 
• Each response option is 
depicted in a picture with a 
generic figure together with an 
appropriate color. Words are 
written under each of the 
pictures as well, but no 
numbers are evident to the 
patients completing the tool.  
• Lower psychometric strength 
General Fatigue Scale74 1 
• Measures fatigue intensity, 
distress levels and disruption 
of daily activities.  
• Psychometrics not complete 
 
 
  
   
 
  32 
 
Table 4 
Clinical Usefulness of Recommended Measures 
Measure Equipment Needed Cost 
Ease of 
Use 
Scoring/ 
Interpretation 
Normative 
Data 
Brief Fatigue 
Inventory No High Easy Easy No 
Cancer Related 
Fatigue Distress 
Scale 
No None Moderate Easy No 
10-point 
Numeric Rating 
Scale for 
Fatigue 
No None Easy Easy No 
MD Anderson 
Symptom 
Inventory 
No High Easy Easy No 
Wu Cancer 
Fatigue Scale No None Easy Easy No 
Multidimensional 
Fatigue 
Symptom 
Inventory 
No None Easy Easy No 
Bi-dimensional 
Fatigue Scale No none Easy Easy No 
Cancer Fatigue 
Scale No None Easy Easy No 
Fatigue 
Symptom 
Inventory 
No None Easy Easy No 
Multidimensional 
Fatigue 
Inventory 
No None Moderate Moderate No 
Piper/Quick 
Piper No None Easy Easy No 
Profile of Mood 
States 
No 
 None Easy Easy 
Yes in 
Athletes 
PROMIS Cancer 
Fatigue Short 
Form 
No None Easy Easy No 
   
 
  33 
 
Schwartz 
Cancer Fatigue 
Scale 
No None Easy Easy No 
Abbreviations: PROMIS: Patient Reported Outcome Measurement Information System  
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Table 5 2 
Psychometric properties of Recommended Measures Related to Reliability and Responsiveness 3 
Test Test-retest Reliability and Internal Consistency Responsiveness 
Unidimensional Tools – Highly Recommended 
Brief Fatigue 
Inventory (BFI) 
Test-retest Reliability 
r = 0.90-0.9338,45,47 
ICC = 0.969 
 
Internal Consistency 
Inter-item correlation: ICC = 0.64 (0.46-
0.81)9 
 
Fatigue Severity 
Cronbach α = 0.92-9641,42,49 
 
Functional Interference 
Cronbach α = 0.90-0.9541,42,49 
 
Global Fatigue 
Cronbach α = 0.94-0.979,41-46 
 
 
Cancer Related 
Fatigue Distress 
Scale 
Internal Consistency 
 
Cronbach α = 0.95-0.9822 
 
 
10-point Numeric 
Rating Scale for 
Fatigue 
Test-retest Reliability 
r = 0.8816 
ICC = 0.57 (absolute agreement)18 
 
Diagnostic Accuracy 
Sensitivity  
 = 85%16  
 = 70%19 
Specificity   
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 = 61%16 
 = 71%19 
Area under the Curve = 0.7119 
Cut Score = 42 
Cut Score = 519  
 
Unidimensional Tools – Recommended 
MD Anderson 
Symptom 
Inventory (MDASI) 
(fatigue only) 
Internal Consistency 
Symptom Severity (fatigue included): 
Cronbach  α = 0.85-0.8724,25 
 
 
Wu Cancer Fatigue 
Scale 
Internal Consistency:  
Full Scale (15 items) 
Cronbach α = 0.9527 
 
Full Scale (9 items) 
Cronbach α = 0.9126 
 
Physical and Emotional Subscale 
Cronbach α = 0.9427 
 
Cognitive Subscale 
Cronbach α = 0.8627 
 
 
Multidimensional Tools – Highly Recommended 
Multidimensional 
Fatigue Symptom 
Inventory (MFSI) 
Internal Consistency: 
Cronbach α = 0.83 – 0.9628,52 
 
By subscale:29 
General - Cronbach α = 0.96 
Emotional - Cronbach α = 0.92 
Physical - Cronbach α = 0.87 
Mental - Cronbach α = 0.91 
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Vigor - Cronbach α = 0.90 
 
Multidimensional Tools – Recommended 
Bi-dimensional 
Fatigue Scale 
Internal Consistency:30 
Full scale 
Omega hierarchical = 0.89 
 
Mental and physical subscales  
Cronbach α = 0.96  
Cut score = 1153 
 
Effect Size30 
d = 1.19 (11-item) 
d = 1.15 (9-item)  
Cancer Fatigue 
Scale 
Test–retest Reliability: 
r = 0.6931 
 
Internal consistency (15 items): 
Cronbach α= 0.8831 
 
 
Fatigue Symptom 
Inventory (FSI) 
Test-retest Reliability:  
r=0.35-0.7560  
 
Internal Consistency:  
Full scale 
Cronbach α = 0.9432,59  
 
Severity subscale  
Cronbach α = 0.8957  
 
Interference subscale  
Cronbach α = 0.9157 
  
Younger Participants 
Cronbach α = 0.9232 
 
Older Participants 
Cronbach α= 0.9432 
Effect Size:57  
Severity = -0.24 
Interference = -0.35 
Duration = -0.09 
 
Standardized Response Mean:57  
Severity = -0.21 
Interference = -0.38 
Duration = -0.08 
 
Cut score ≥3 points:62  clinically significant 
fatigue 
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Survivors with breast cancer  
Cronbach α =0.9332 
 
Other cancer  
Cronbach α= 0.9432 
 
 
Piper/Quick Piper 
(PFS) 
PFS-R (22-item scale) 
Test-retest Reliability: 
 
Sensory Subscale 
r = 0.6073 
 
Affective meaning Subscale 
r = 0.6873 
 
Cognitive/mood Subscale 
r = 0.6373 
 
Behavioral/severity Subscale 
r = 0.8173 
 
Internal Consistency: 
Total Scale 
Cronbach α = 0.95-0.9634,73 
 
Sensory Subscale 
Cronbach α = 0.89-0.9534,73 
 
Affective meaning Subscale 
Cronbach α = 0.94-0.9334,73 
 
No evidence 
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Cognitive/mood Subscale 
Cronbach α = 0.80-0.9234,73 
 
Behavioral/severity Subscale 
Cronbach α = 0.93-0.9734,73 
 
QuickPIPER (15-item scale) 
Test-retest Reliability: 
r = 0.94767 
 
PFS -12 (12- item scale) 
Test-retest Reliability:  
 
r = 0.9268  
 
Multidimensional 
Fatigue Inventory 
(MFI) 
Internal Consistency 
20 Item Scale: 
Cronbach α = 0.80-0.9433,63,64,81-83  
 
15 Item Scale 
 Cronbach α = 0.9065 
 
Test-retest Reliability 
r = 0.76-0.83 total score63,65  
 
Physical Scale Effect size = 0.4963  
Profile of Mood 
States (POMS) 
Internal Consistency: 
Fatigue Subscale 
Cronbach α = 0.9176  
 
Vigor Subscale 
Cronbach α = 0.9276  
 
Total Scale 
MCID = 5.677 
 
Per each item 
MCID = 1.177 
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PROMIS Cancer 
Fatigue Short Form 
Internal consistency:  
Cronbach α = 0.87-0.8836  
 
 
Schwartz Cancer 
Fatigue Scale 
Internal Consistency: 
Cronbach α = 0.9637 
MCID77 
Total Scale = 5.0 
Increased Fatigue = 5.7 
Decreased Fatigue = -2.1  
Effect size = 0.71  
 
Abbreviations: ICC = intraclass correlation coefficient; MCID: Minimal clinically important difference; r = Pearson’s r 4 
 5 
 6 
  7 
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Table 6 8 
Psychometric properties of Recommended Measures Related to Validity  9 
 Criterion Validity  Construct validity  
 Concurrent  Predictive  Convergent  Discriminant 
Unidimensional Tools – Highly Recommended 
Brief Fatigue 
Inventory (BFI) 
With Vitality Subscale SF36:  
r= -0.67 (-0.73 to -0.59)9 
 
With FFIS: 
r= 0.8235 
 
With the Four Item Fatigue 
Screen: 
Spearman rho = 0.69-0.73 
(0.50-0.90)36,37 
 
BFI Worst Fatigue38  
 with MSAS-SF: r = 0.67   
 with FACIT-F: r = -0.71 
 
BFI Usual Fatigue38  
 with MSAS-SF: r = 0.68 
 with FACIT-F: r = -0.75 
 
BFI Current Fatigue38  
 with MSAS-SF: r = 0.60 
 with FACIT-F: r = -0.69 
 
BFI Global Fatigue38  
 with MSAS-SF: r=0.72 
 with FACIT-F: r=-0.77 
 
 Unidimensionality: 68% of the 
variance explained by one 
factor9 
 
BFI Single Factor Loading = 
0.80-0.9439,41 
  
BFI Worst Fatigue39 
 with POMS fatigue: r = 0.82 
 with POMS vigor: r = -0.69 
 
BFI Fatigue Severity39 
 with POMS fatigue: r = 0.87 
 with POMS vigor: r = -0.71 
 
 
With ECOG: 
(p<0.001)9 
 
Between high, low 
KPS39  
p<0.001 
With in-, outpatients39 
p<0.01 
 
 
Cancer Related 
Fatigue Distress 
Scale 
Content Validity Index =  
0.60-1.00 (mean 0.91)19 
 
 Single factor loading = 0.59-
0.9119 
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One Item Fatigue 
Scale 
With FSI Severity Subscale: 
Spearman’s rho = 0.8716 
 
With FACIT-F:  
Spearman’s rho =  -0.7516 
 
 
With HADS Depression 
subscale: 
Spearman’s rho = 0.5616 
 
 
  With, without fatigue: 
ROC AUC = 0.8716 
 
Unidimensional Tools – Recommended 
MD Anderson 
Symptom 
Inventory 
(MDASI) 
With EORTC QLQ-C30: 
r = -0.6022 
 
With BFI Worst Pain 
R = 0.8422  
 
 General Symptoms factor 
loading >0.347 
Fatigue factor loading = 0.68-
0.8321,47 
 
Between poor and 
good functional status: 
 p<0.0121,47 
Wu Cancer 
Fatigue Scale 
(WCFS) 
With GDS 
 r = 0.60-0.6123,24 
 
With CRFDS 
r = 0.73-0.8323,24 
 
 
With SCFS: 
 r = 0.78-0.8423,24  
 
With GDS fatigue: 
r = 0.59-0.6823,24 
 
Single factor item analysis: 
r = 0.65-0.8624 
 
 
Multidimensional Tools – Highly Recommended 
Multidimensional 
Fatigue 
Symptom 
Inventory – SF 
(MFSI- SF) 
With POMS-fatigue: 
r = 0.63 – 0.8925 
 
With SF-36 (vitality): 
r = 0.46 – 0.8025 
 Confirmatory factor analysis: 
45.2 - 61.15% (four 
factors)25,49; 
With comparable fit index: 
0.9026 
Between individuals 
with cancer and 
healthy controls: 
p <0.00149 
p <0.0525 
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With BDI: 
r = 0.6849  
 
With SF-36 – vitality:  
r = -0.62-0.7825,49 
 
With STAI: 
r = 0.51 – 0.8025 
 
With CES-D 
r = 0.63 - 0.8025 
 
With FSI: 
r = 0.7426 
 
With HADS – depression: 
r = 0.77548 
 
With HADS – anxiety  
r = 0.70148 
 
Divergent validity: 
With MC-20: 
r = -0.20 to -0.3025 
 
Between different 
ECOG Performance 
Status: 
p <0.0525 
Multidimensional Tools – Recommended 
Bi-dimensional 
Fatigue Scale 
 Predictive 
Validity:50 
Sensitivity = 92% 
Specificity = 53% 
PPV = 46% 
NPV = 94% 
 HADS – depression: 
r =  0.4027 
 
HADS – anxiety: 
r = 0.3727 
 
WSAS: 
r = 0.3627 
 
MFIS: 
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r = 0.2427 
 
Cancer Fatigue 
Scale (CFS) 
With FNS: 
 r = 0.4450 
  Factor analysis28  
 physical fatigue:  0.77-0.86 
 cognitive fatigue:  0.78-0.82 
 affective fatigue: 0.73-0.81 
 
With VAS for fatigue: 
r = 0.6728 
 
With SCFR-r: 
r = 0.6256 
 
With FSI: 
r = 0.6256 
 
Divergent validity with hope: 
r = - 0.21 to -0.2556  
Between severe and 
moderate levels of 
fatigue:  p<0.00152 
 
Extent of disease: 
p=0.02852 
 
Type of treatment: 
p < 0.0552 
 
Between having/not 
having a caregiver: 
p = 0.00152 
 
Between high and low 
function: 
p = 0.02956 
 
Between 3 levels of 
depression: 
p <0.000156 
 
Fatigue 
Symptom 
Inventory 
With SF36 vitality scale: 
r = -0.68 to -0.7754 
 
With the FFIS: 
r = 0.8035 
 
With ZSDS: 
r = 0.41 - 0.7155 
 
With MFSI-SF total: 
r =0.7426 
 
 Intensity with POMS-F: 
r = 0.65 – 0.7557 
 
Duration with POMS-F: 
r = 0.64 – 0.7157 
 
Interference with POMS-F: 
r = 0.7857 
 
Between active, 1 year, 
and >1 year post 
treatment:29 
 Intensity (avg 
fatigue): 
 p <0.05 
 Duration:  p <0.05 
 Interference: p <0.01 
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Severity scale with One-Item 
Fatigue Screen: 
r = 0.8716 
 
With CES-D: 
r = 0.37-0.6329 
 
With SLDS-C 
r = -0.46 to -0.6129 
 
Multidimensional 
Fatigue 
Inventory (MFI) 
With the POMS-fatigue: 
r = 0.6862 
 
With POMS-vigor: 
r = -0.72 to -0.7460,62 
 
With HADS-Depression: 
r = 0.65 – 0.7761,62 
 
With HADS-Anxiety: 
r = 0.41 – 0.5130,62 
 
With Quality of Life: 
r = -0.6762 
 
 
 With NRS-fatigue 
Spearman’s rho = 0.5780 
 
With VAS-general fatigue: 
r = 0.77 – 0.8360,82 
 
With EORTC QLQ-3080 
Spearman’s rho = 0.53 
 
Multidimensional Scale:  
 -confirmed via confirmatory 
 factor analysis with 
 comparative fit index = 0.88280 
-confirmed via adjusted 
goodness of fit >0.90.61 
 
With POMS-Anxiety: 
r = 040 - 0.4660,62 
 
With POMS-Depression: 
r = 0.37 – 0.4660,62 
 
With SF-36: 
r = 0.-49 to -0.6581 
 
With STAI: 
Between different 
fatigue levels/groups: 
p<0.00161,81 
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r = 0.50 – 0.6281 
 
Piper/Quick 
Piper (PFS) 
With POMS-fatigue: 
r = 0.50 to 0.8063,64,70 
 
With POMS-vigor: 
r = -0.13 to -0.4463,64,70 
 
QuickPiper with R-PFS: 
r = 0.9864 
 
With MDFI: 
r = 0.56 - 0.7668 
ROC AUC 0.74364 QuickPiper Factor analyses 
>0.6064 
 
With MFI: 
r = 0.60 – 0.8467 
 
With RSCL: 
r = 0.54 – 0.7467 
 
With BDI: 
r = 0.5569 
 
With KPS: 
r = -0.2969 
 
Between lung/breast 
cancer patients with 
different fatigue levels: 
p>0.00167 
 
Between active 
chemotherapy and no 
treatment: 
p>0.00167 
Profile of Mood 
States (POMS) 
With BFI: 
r = 0.8441  
 
 POMS-fatigue = 83% of total 
variance60 
 
With LFS – fatigue: 
r = 0.5360 
With LFS – energy: 
r = -0.3560 
 
With MFI: 
r = - 0.4160 
 
PROMIS Cancer 
Fatigue Short 
Form 
With FSI – Severity: 
r = 0.72 – 0.7833 
With CES-D:33 
r = 0.51 – 0.56  
 
With STAI: 
r = 0.4533 
 
With SF-36 – vitality: 
 Goodness of fit: 
CFI = 0.9433 
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r = -0.66 to -0.7733 
Schwartz Cancer 
Fatigue Scale 
  Factor analysis = 70% of total 
variance34 
 
Content validity was achieved 
on 4 words; “listless”, “tired”, 
“barely able to move” and 
“dragged-out”.34 
 
With CFS: 
r = 0.6256 
 
With FSI: 
r = 0.6856 
 
Divergent with Hope: 
r = -0.1656 
Between good and poor 
function on KPS: 
p=0.00256 
 
Between depression/no 
depression on HADS: 
p<0.00156 
Abbreviations: BDI:  Beck Depression Inventory; BFI:  Brief Fatigue Inventory; CES-D:  Center for Epidemiological Studies-Depression Scale; CFS: Cancer Fatigue Scale; CRFDS:  10 
Cancer Related Fatigue Distress Scale; ECOG: Eastern Cooperative Oncology Group; EORTC QLQ-30:  European Organisation for Research and Treatment of Cancer Quality of Life 11 
Questionnaire 30; FACIT-F:  Functional Assessment of Chronic Illness Therapy-Fatigue; FACIT-F: Functional Assessment of Chronic Illness Therapy – Fatigue; FFIS: Fatigue and 12 
Functional Impact Scale; FNS:  Fatigue Numerical Scale; FSI: Fatigue Symptom Inventory; GDS: Geriatric Depression Scale; HADS:  Hospital Anxiety and Depression Scale; KPS:  13 
Karnofsky Performance Score; LFS: Lee Fatigue Scale; MC-20:  Marlon-Crowne Desirability Scale; MDASI: MD Anderson Symptom Inventory; MFI: Multi-dimensional Fatigue 14 
Inventory; MFIS:  Modified Fatigue Impact Scale; MFSI-20: Multidimensional Fatigue Symptom Inventory; MSAS-SF: Memorial Symptom Assessment Scale Short Form; NRS-Fatigue:  15 
Numerical Rating Scale-Fatigue; PFS: Piper Fatigue Scale; POMS:  Profile of Mood States; RSL:  Rotterdam Symptom Checklist; SCFR-r: Schwartz Cancer Fatigue Scale – revised; 16 
SCFS: Schwartz Cancer Fatigue Scale; SF-36: Medical Outcomes Questionnaire Short Form; SLDS-C: Satisfaction with Life Domains Scale for Cancer; STAI: State Trait Anxiety 17 
Index; VAS: Visual Analog Scale; WCFS: Wu Cancer Fatigue Scale; WSAS: Work and Social Adjustment Scale; ZSDS: Zung Self-Rating Depression Scale 18 
Other Abbreviations: CFI:  Confirmatory Factor Analysis; NPV: negative predictive value; PPV: positive predictive value; r = Pearson’s r; ROC AUC: Receiver Operator Characteristic 19 
Curve, Area Under the Curve 20 
 21 
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Appendix: Search Terms 22 
 23 
Bidimensional Fatigue Scale 24 
Brief Fatigue Inventory 25 
Cancer Fatigue Scale 26 
Cancer Related Fatigue Distress Scale 27 
Diagnostic Interview Guide for Cancer Related Fatigue 28 
European Organization for Research and Treatment of Cancer Quality of Life 29 
Questionnaire  (EORTC) 30 
Fatigue and Functional Impact Scale 31 
Fatigue Barriers Scale 32 
Fatigue Management Barriers Questionnaire (FMBQ) 33 
Fatigue Pictogram  34 
Fatigue Scale- Children  35 
Fatigue Symptom Checklist 36 
Fatigue Symptom Inventory 37 
Four-Item Fatigue Scale 38 
Functional Assessment of Cancer Therapy 39 
General Fatigue Scale 40 
Illness Perception Questionnaire 41 
Karnofsky Performance Scale 42 
Lee Fatigue Scale 43 
MD Anderson Symptom Inventory 44 
Measuring Fatigue in Childhood Cancer 45 
Medical Outcome Study QOL Short Form 36 46 
Memorial Symptom Assessment Scale- Short Form (MASAS-SF) 47 
Modified Brief Fatigue Inventory 48 
Multidimensional Assessment of Fatigue 49 
Multidimensional Fatigue Inventory (MFI) 50 
Multidimensional Fatigue Symptom Inventory (MFSI) 51 
One-Item Fatigue Scale 52 
PEDS QL Multidimensional Fatigue Scale 53 
Piper Fatigue Scale 54 
Play Performance Scale for Children 55 
Profile of Mood States (POMS) 56 
PROMIS Cancer Fatigue Short Form 57 
QOL for Children with Cancer 58 
Quick Piper Scale 59 
Rotterdam Symptom Checklist 60 
Schwartz Cancer Fatigue Scale 61 
Spielberger State Trait Anxiety 62 
Visual Analog Scale 63 
Wu Cancer Fatigue Scale 64 
Zung Self Rating Depression Scale 65 
 66 
